Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Grace Therapeutics, Inc
Bullboard Posts
User Avatar Image
(17)
•••
Comment by CanukInvestoron Dec 17, 2019 10:49am
135 Views
Post# 30463454

RE:RE:RE:RE:Great day

RE:RE:RE:RE:Great day Agreed, ACST is up to bat, there is a 101MPH fast ball and we're swinging for the fence........

Home-Run Hitters, At Bat With Acasti Pharma

Acasti Pharma Inc. (ACST)

Summary

  • ACST’s drug, CaPre, promises to be the best-in-class Omega 3 play, used to lower triglycerides. It was recently trading at $1.01/share, with a market cap of $79M.
  • The biggest competitor to CaPre is Amarin's drug Vascepa. After September 2018 study results, AMRN increased from $3/share to $19.01/share recently, or a market cap of $6.29B.
  • The triglyceride-lowering market is large, but CaPre also potentially improves cholesterol, unlike any other Omega 3 play. If this is confirmed, CaPre becomes a game-changer.
  • Two of the biggest investors in ACST are arguably two of the smartest investors in biotech: Joe Edelman of Perceptive and the legendary George Haywood. Both have been accumulating.
  • If positive Phase III Trial results are a 30% probability (and it would appear that it's significantly higher), then the price should be $8.29/share (leading into December 2019).
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities